StockIQ.techIncyte Corporation (INCY) Stock Analysis
Free AI-powered analysis and research for Incyte Corporation stock
Sector: Healthcare
INCY snapshot
Data as of 3 Nov 2026 close. Updated daily.
Incyte Corporation scores 77/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 66% of its 52-week range, up 15.8% over the past year. Latest reported figures show a profit margin of 6.7%, return on equity of 7.8% and revenue growth of +14.0%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- High P/E (61.4): -10
- Low Debt (0.01 D/E): +8
- Strong Liquidity (3.84 Current Ratio): +8
- Above MA200: +4
- Healthy Momentum (+15.8% over 1 year): +7
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full INCY report
Incyte Corporation (INCY) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze INCY Now →📰 Latest Update
Incyte (INCY) Q3 2026 Earnings Call Transcript
Thu, October 29, 2026 at 10:45 PM UTC 2 min read
Incyte (INCY) reported its Q3 2026 earnings, showcasing a significant increase in revenue driven by strong sales of its key oncology products. The company's robust pipeline and ongoing clinical trials suggest potential for future growth, making it an attractive option for investors seeking exposure in the biotech sector. However, investors should monitor the competitive landscape and regulatory developments that could impact Incyte's market position.